Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Leqembi Subcutaneous Autoinjector Approved in China
Eisai said on September 3 that their subcutaneous autoinjector formulation of Leqembi (lecanemab) has been approved in China for the initiation treatment of early Alzheimer’s disease (AD).The approval covers patients with mild cognitive impairment due to AD or mild AD…
To read the full story
Related Article
- Leqembi Subcutaneous Autoinjector Gets Priority Review in China
February 10, 2026
- China Accepts BLA for Leqembi Subcutaneous Autoinjector: Eisai
January 7, 2026
BUSINESS
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Halaven Generics Obtain Soft Tissue Sarcoma Use
September 3, 2026
- Ono Teams with Aitia in AI-Driven Neurology Drug Discovery
September 3, 2026
- Nippon Kayaku’s Generic Sunitinib Gains Pancreatic NET Use
September 3, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…